NewGenIvf Group Ltd. (NIVF) intrinsic value & 10-year financials
NewGenIvf Group Ltd. (NIVF) has a Graham intrinsic value of $100.98 per share. At $1.15 on Oct 27, 2026, the stock trades 99% below that value. Over the last 6 fiscal years revenue grew 54.9% a year to $23.7M, with an average return on invested capital of 68.9%.
- Graham intrinsic value
- $100.98
- Share price (Oct 27, 2026)
- $1.15
- Price vs Graham value
- 99% below
- Market cap
- $3.7M
- Revenue (FY2025)
- $23.7M
- Revenue growth (6-yr CAGR)
- 54.9%
- ROIC (10-yr avg)
- 68.9%
- Free cash flow (FY2025)
- -$11.1M
NIVF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $23.7M | $9.9M | $3.04 | -$11.1M | -45.2% | 80.2% |
| FY2024 | $371.7K | -$524.6K | -$0.64 | -$8.3M | -312.2% | 225.0% |
| FY2023 | $446.0K | $130.2K | $0.18 | -$1.8M | 9.5% | 14.9% |
| FY2022 | $506.3K | $458.7K | $0.80 | $1.6M | 78.7% | 35.0% |
| FY2021 | $4.1M | -$533 | $0.00 | $1.4M | 4.8% | -10.5% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NewGenIvf Group Ltd revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NewGenIvf Group Ltd has earned high returns on invested capital, averaging 24.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
NewGenIvf Group Ltd capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NewGenIvf Group Ltd is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $100.98 per share.